Format

Send to

Choose Destination
Breast Cancer Res. 2011 May 25;13(3):107. doi: 10.1186/bcr2842.

From bone to breast and back - the bone cytokine RANKL and breast cancer.

Abstract

Receptor activator of nuclear factor-κB ligand (RANKL) plays a pivotal role in regulating bone homeostasis. Osteoporosis and malignant bone disease secondary to breast cancer are characterized by enhanced RANKL production and increased bone turnover. Thus, denosumab, a monoclonal antibody to RANKL, has been developed and is now approved for various bone loss conditions. Recent results indicate that RANKL may also promote the development and osseous migration of breast cancer.

PMID:
21635706
PMCID:
PMC3218926
DOI:
10.1186/bcr2842
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center